Begue S, Morel P, Djoudi R
Direction médicale, établissement français du sang, 20, avenue du Stade-de-France, 93218 La Plaine-Stade-de-France, France.
Établissement français du sang - Bourgogne-Franche Comté, 8, rue du Docteur-Jean-François-Xavier-Girod, 25000 Besançon, France.
Transfus Clin Biol. 2016 Nov;23(4):245-252. doi: 10.1016/j.tracli.2016.07.001. Epub 2016 Sep 5.
If technological innovations are not enough alone to improve blood safety, their contributions for several decades in blood transfusion are major. The improvement of blood donation (new apheresis devices, RFID) or blood components (additive solutions, pathogen reduction technology, automated processing of platelets concentrates) or manufacturing process of these products (by automated processing of whole blood), all these steps where technological innovations were implemented, lead us to better traceability, more efficient processes, quality improvement of blood products and therefore increased blood safety for blood donors and patients. If we are on the threshold of a great change with the progress of pathogen reduction technology (for whole blood and red blood cells), we hope to see production of ex vivo red blood cells or platelets who are real and who open new conceptual paths on blood safety.
如果仅靠技术创新不足以提高血液安全性，那么它们在输血领域几十年的贡献也是巨大的。献血方面的改进（新型血液成分单采设备、射频识别技术）、血液成分方面的改进（添加剂溶液、病原体灭活技术、血小板浓缩物自动化处理）或这些产品制造过程的改进（通过全血自动化处理），所有这些实施了技术创新的步骤，都使我们实现了更好的可追溯性、更高效的流程、血液制品质量的提高，从而提高了献血者和患者的血液安全性。如果随着病原体灭活技术（针对全血和红细胞）的进步，我们正处于重大变革的边缘，那么我们希望看到真正的体外红细胞或血小板的生产，它们会为血液安全开辟新的概念路径。
